Bank of America Corp DE Sells 238,909 Shares of Medline $MDLN

Bank of America Corp DE reduced its position in Medline (NASDAQ:MDLN) by 9.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 2,288,251 shares of the company’s stock after selling 238,909 shares during the period. Bank of America Corp DE’s holdings in Medline were worth $101,827,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in MDLN. Carlyle Group Inc. acquired a new stake in Medline in the 4th quarter worth approximately $9,042,728,000. H&F Corporate Investors X Ltd. acquired a new position in shares of Medline in the 4th quarter valued at $4,179,591,000. Vanguard Group Inc. purchased a new position in Medline in the 4th quarter worth $793,278,000. Morgan Stanley acquired a new stake in Medline during the 4th quarter worth about $636,807,000. Finally, Capital Research Global Investors acquired a new stake in Medline during the 4th quarter worth about $620,937,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. BNP Paribas Exane decreased their target price on Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. BMO Capital Markets reissued an “outperform” rating and set a $47.00 price target on shares of Medline in a research report on Thursday. Truist Financial decreased their price objective on shares of Medline from $56.00 to $47.00 and set a “buy” rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft set a $37.00 price target on Medline in a research report on Thursday. Finally, Robert W. Baird set a $42.00 price objective on shares of Medline in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Insider Activity at Medline

In related news, major shareholder Private Ltd Gic sold 1,976,618 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $35.60, for a total value of $70,367,600.80. Following the transaction, the insider directly owned 25,264,760 shares of the company’s stock, valued at approximately $899,425,456. This trade represents a 7.26% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jessi L. Corcoran acquired 5,000 shares of the business’s stock in a transaction on Friday, June 5th. The shares were purchased at an average price of $34.15 per share, with a total value of $170,750.00. Following the completion of the purchase, the insider owned 5,000 shares in the company, valued at $170,750. This represents a ? increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have sold 2,348,612 shares of company stock valued at $83,654,149. 0.81% of the stock is owned by corporate insiders.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
• Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
• Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
• Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation

Medline Price Performance

Medline stock opened at $35.23 on Friday. The company’s fifty day moving average price is $38.22 and its 200 day moving average price is $41.72. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The stock has a market capitalization of $46.28 billion and a P/E ratio of 110.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.51 and a current ratio of 4.33.

Medline (NASDAQ:MDLN) last announced its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.18. The company had revenue of $7.68 billion during the quarter. As a group, equities research analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.